Akers Biosciences (AKER) Receiving Somewhat Positive Press Coverage, Analysis Shows

Press coverage about Akers Biosciences (NASDAQ:AKER) has trended somewhat positive recently, according to Accern. The research group ranks the sentiment of press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Akers Biosciences earned a coverage optimism score of 0.17 on Accern’s scale. Accern also gave news coverage about the medical instruments supplier an impact score of 45.536312325437 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

These are some of the news articles that may have effected Accern Sentiment Analysis’s scoring:

Separately, ValuEngine upgraded shares of Akers Biosciences from a “sell” rating to a “hold” rating in a research report on Friday, December 1st.

Akers Biosciences (NASDAQ:AKER) traded up $0.08 during mid-day trading on Friday, hitting $0.66. 16,632,404 shares of the stock were exchanged, compared to its average volume of 18,076,666. Akers Biosciences has a one year low of $0.12 and a one year high of $2.90. The company has a market capitalization of $16.78, a price-to-earnings ratio of -1.10 and a beta of -0.99.

COPYRIGHT VIOLATION NOTICE: This article was published by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this article on another website, it was stolen and reposted in violation of international trademark and copyright laws. The correct version of this article can be accessed at https://sportsperspectives.com/2018/03/11/akers-biosciences-aker-receiving-somewhat-positive-press-coverage-analysis-shows.html.

About Akers Biosciences

Akers Biosciences, Inc, together with its subsidiaries, develops, manufactures, and supplies rapid screening and testing products designed to deliver healthcare information to healthcare providers and consumers in the United States and internationally. The company’s marketed products include BreathScan, a disposable breath alcohol detector; BreathScan PRO, a quantitative breath alcohol detection system; METRON, a disposable breath ketone device to monitor ketosis; and BreathScan Lync, a non-invasive, quantitative measurement of biological markers for health and wellness.

Insider Buying and Selling by Quarter for Akers Biosciences (NASDAQ:AKER)

Receive News & Ratings for Akers Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akers Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply